Table 1.
Characteristics of the Study Participants in the BMS and MPS Groups
| Characteristics | BMS group (n=35) | MPS group (n=67) | p-value |
|---|---|---|---|
| Demographic factors | |||
| Sex | 0.38 | ||
| Female | 11 (31.4) | 27 (40.3) | |
| Male | 24 (68.6) | 40 (59.7) | |
| Age at treatment, yr | 70 (62–74) | 70 (62–77) | 0.44 |
| BMI, kg/m2 | 23.6±3.5 | 22.0±3.4 | 0.028 |
| Smoking | 14 (40.0) | 24 (35.8) | 0.68 |
| Clinical factors | |||
| Underlying disease | |||
| Hypertension | 14 (40.0) | 34 (50.8) | 0.30 |
| Diabetes | 5 (14.3) | 10 (14.9) | 0.93 |
| CKD | 0 | 1 (1.5) | >0.99* |
| Chronic hepatitis | 0 | 3 (4.5) | 0.55* |
| History of biliary disease | 6 (17.1) | 10 (14.9) | 0.77 |
| Previous hepatectomy | 0 | 3 (4.5) | 0.20* |
| Bismuth type | 0.21 | ||
| I | 0 | 3 (4.5) | |
| II | 3 (8.6) | 4 (6.0) | |
| IIIa | 11 (31.4) | 13 (19.4) | |
| IIIb | 1 (2.9) | 9 (13.4) | |
| IV | 20 (57.1) | 38 (56.7) | |
| Clinical stage | 0.86 | ||
| IIIc | 9 (25.7) | 20 (29.9) | |
| IVa | 16 (45.7) | 27 (40.3) | |
| IVb | 10 (28.6) | 20 (29.9) | |
| Pre-procedure total bilirubin, mg/dL | 6.6 (2.0–14.1) | 5.8 (2.3–13.8) | 0.85 |
| PT INR | 1.1 (1.0–1.1) | 1.0 (1.0–1.1) | 0.73 |
| Albumin, g/dL | 3.6 (3.4–4.0) | 3.7 (3.2–4.1) | 0.76 |
| ECOG performance status | 0.55* | ||
| 1 | 35 (100.0) | 64 (95.5) | |
| 2+ | 0 | 3 (4.5) | |
| Treatment factors | |||
| Emergent procedure | 0 | 5 (7.5) | 0.16* |
| Treatment | 0.76 | ||
| No treatment | 31 (88.6) | 59 (88.1) | |
| Chemotherapy | 4 (11.4) | 6 (9.0) | |
| Radiotherapy | 0 | 1 (1.5) | |
| Photodynamic therapy | 0 | 1 (1.5) |
Data are presented as the number (%), median (interquartile range), or mean±SD.
BMS, bilateral metal stents; MPS, multiple plastic stents; BMI, body mass index; CKD, chronic kidney disease; PT, prothrombin time; INR, international normalized ratio; ECOG, Eastern Cooperative Oncology Group.
*Fisher exact test.